Prague C and M criteria for Barrett oesophagus is an internationally validated, standardised endoscopic classification system designed to quantify and document the circumferential (C) and maximal (M) longitudinal lengths of columnar-lined epithelium within the distal oesophagus1. Developed to eliminate the high interobserver variability inherent in subjective visual descriptions, the Prague system provides reproducible anatomical landmarks that guide clinical risk stratification, endoscopic surveillance intervals, and therapeutic interventions for patients with chronic gastro-oesophageal reflux disease (GORD)1. Accurate application of this scoring system requires precise identification of the proximal margin of the gastric folds and the squamocolumnar junction (Z-line), ensuring standardized clinical communication across gastroenterology and pathology multidisciplinary teams.

Etiology & Risk Factors

  • Chronic Gastro-oesophageal Reflux Disease (GORD): Prolonged and severe exposure of the distal oesophageal squamous mucosa to gastric acid, pepsin, and duodenal-biliary contents is the primary underlying driver of columnar metaplasia1.
  • Hiatus Hernia: Large axial hiatus hernias structurally compromise the lower oesophageal sphincter barrier and promote acid reflux, directly correlating with increased circumferential (C) and maximal (M) Prague lengths.
  • Demographic Predisposition: Caucasian males over the age of 50 years exhibit a significantly higher incidence and prevalence of Barrett oesophagus compared to females and non-Caucasian populations.
  • Lifestyle and Metabolic Factors: Central adiposity (elevated waist circumference and visceral obesity), tobacco smoking, and diets high in processed fats substantially increase the risk of malignant progression from non-dysplastic Barrett oesophagus to oesophageal adenocarcinoma.
  • Genetic and Familial Factors: A positive family history of Barrett oesophagus or oesophageal adenocarcinoma in a first-degree relative confers an elevated susceptibility, indicating complex polygenic risk contributions.

Pathophysiology

The development of Barrett oesophagus is conceptualized as a classic paradigm of chronic tissue injury, inflammation, and adaptive cellular reprogramming1. Under the continuous chemical assault of hydrochloric acid and conjugated bile acids, the delicate stratified squamous epithelium of the distal oesophagus undergoes ulceration and chronic erosion. During the subsequent tissue repair process, pluripotent stem cells located within the basal layer of the oesophageal ducts and glands—or surviving submucosal elements—undergo altered differentiation pathways. Instead of regenerating normal stratified squamous cells, these stem cells differentiate into columnar mucin-secreting cells (gastric fundic-type, junctional-type, or specialised intestinal metaplasia characterised by goblet cells)1. This adaptive columnar-lined epithelium is more resistant to acidic degradation than squamous epithelium, yet it exists in an unstable pre-malignant state. Persistent oxidative stress, chronic DNA damage, and inflammatory cytokine signaling within this metaplastic environment can induce somatic mutations (such as p53 alterations and chromosomal instability), driving the stepwise progression from non-dysplastic Barrett oesophagus through low-grade dysplasia, high-grade dysplasia, and ultimately invasive oesophageal adenocarcinoma.

Prague C and M criteria for Barrett oesophagus — Pathophysiological Cascade & Clinical Flowchart 1 Chronic GORD Acid and duodenogastrooesophageal reflux injures the stratified squamous epithelium of the distal oesophagus. 2 Columnar Metaplasia Chronic caustic injury drives metaplastic transformation of normal squamous epithelium into columnar-lined epithelium containing goblet cells. 3 Endoscopic Identification During upper endoscopy, the squamocolumnar junction (Z-line) and gastro-oesophageal junction (gastric folds) are identified to systematically measure the C and M values of the Prague criteria. 4 Dysplastic Progression Untreated or uncontrolled chronic inflammation can provoke low-grade dysplasia, high-grade dysplasia, and ultimately invasive oesophageal adenocarcinoma. 5 Eradication and Surveillance Endoscopic eradication therapy (RFA/EMR) combined with high-dose PPI therapy halts malignant transformation and ablates dysplastic tissue.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms:
    • Chronic, long-standing heartburn (pyrosis) occurring two or more times weekly.
    • Acid regurgitation and a sour or bitter taste in the posterior oropharynx.
    • Epigastric or retrosternal burning pain exacerbated by heavy meals, bending over, or recumbency.
    • Dysphagia or odynophagia in advanced stages, which should immediately raise clinical suspicion for peptic stricture, ulceration, or malignant transformation.
    • Silent or atypical presentations (chronic cough, throat clearing, hoarseness, or adult-onset asthma) driven by micro-aspiration of refluxate.
  • Physical Examination & Named Clinical Signs:
    • General physical examination is frequently unremarkable in uncomplicated disease, though signs of central obesity (increased waist-to-hip ratio) are common.
    • Abdominal examination may reveal mild epigastric tenderness upon deep palpation, though generalized tenderness is absent unless a concomitant peptic ulcer or gastritis is present.
    • Absence of physical stigmata does not preclude advanced endoscopic findings; therefore, physical examination serves primarily to rule out acute abdomen, surgical emergencies, or chronic liver disease complications from metabolic dysfunction.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationHigh-resolution upper gastrointestinal endoscopy (EGD) with virtual chromoendoscopy (e.g., NBI, BLI) demonstrating salmon-coloured columnar mucosa extending above the gastro-oesophageal junction, quantified precisely using the Prague C and M criteria, accompanied by Seattle-protocol random biopsies.
Laboratory PanelComplete Blood Count (CBC) to screen for iron-deficiency anaemia secondary to occult or overt gastrointestinal blood loss from Barrett ulceration; renal function panel and electrolytes to establish baseline metrics prior to initiating long-term high-dose proton pump inhibitor therapy.
Imaging / Radiology (X-ray, US, CT, MRI)Barium swallow examination may delineate a sliding hiatus hernia, strictures, or mucosal irregularity, though it lacks sensitivity for flat metaplastic segments. Chest and abdominal contrast-enhanced CT scans are reserved for staging suspected or confirmed dysplastic and malignant lesions.
ECG / Histopathology / ProceduralHistopathological examination of targeted and four-quadrant random biopsies demonstrates specialised intestinal metaplasia characterised by goblet cells containing acidic mucins, with staging graded as non-dysplastic, indefinite for dysplasia, low-grade dysplasia, or high-grade dysplasia.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Prague C Criterion (Circumferential Extent)Measured in centimeters from the proximal margin of the gastric folds (gastro-oesophageal junction) to the highest circumferential point of the squamocolumnar junction. Higher C values correlate with increased risk of neoplastic progression and extensive disease burden.
Prague M Criterion (Maximal Extent)Measured in centimeters from the proximal margin of the gastric folds to the absolute highest point of any isolated tongue or island of columnar mucosa. The M score defines the total longitudinal reach of the Barrett segment.
Vienna Classification of DysplasiaCategorizes mucosal histology into Category 1 (negative for dysplasia), Category 2 (indefinite for dysplasia), Category 3 (low-grade dysplasia), Category 4 (high-grade dysplasia / carcinoma in situ), and Category 5 (invasive carcinoma). Directs surveillance versus therapeutic ablation.
Paris Classification of Superficial LesionsClassifies endoscopic mucosal appearance (Type 0-I protruding, Type 0-IIa superficial elevated, Type 0-IIb flat, Type 0-IIc superficial depressed, Type 0-III excavated) to identify visible neoplastic lesions requiring endoscopic mucosal resection (EMR).

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Reflux Oesophagitis (Los Angeles Grades A-D)Characterized endoscopically by mucosal breaks, linear erosions, and exudative ulcerations limited to the distal squamous epithelium, lacking true columnar-lined mucosal tongues and goblet cell histology on biopsy.
Eosinophilic OesophagitisPresents predominantly with dysphagia and food impaction in younger patients; endoscopy reveals ringed oesphagus, linear furrows, and white exudates, with histology showing dense eosinophil infiltration (> 15 eosinophils per high-power field) and normal distal Z-line architecture.
Hiatus Hernia without MetaplasiaExhibits gastric folds extending above the diaphragmatic hiatus without endoscopic displacement of the squamocolumnar junction or histological evidence of specialised intestinal metaplasia.
Infectious Oesophagitis (Candida, HSV, CMV)Typically presents in immunocompromised hosts with severe odynophagia; endoscopy reveals distinct plaque-like pseudomembranes (Candida), small vesicles and punched-out ulcers (HSV), or deep linear ulcers (CMV), confirmed by viral inclusions or fungal hyphae.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation:
    • Assess hemodynamic stability in patients presenting with acute haematemesis or melaena secondary to deep Barrett ulceration or malignant ulceration; initiate aggressive intravenous access, crystalloid resuscitation, and urgent blood transfusion if indicated.
    • Administer high-dose intravenous proton pump inhibitors (e.g., pantoprazole 80 mg IV bolus followed by 8 mg/h continuous infusion) for acute upper gastrointestinal bleeding prior to urgent therapeutic endoscopy.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Life-long acid suppression with oral proton pump inhibitors to control chronic mucosal inflammation and promote epithelial healing: e.g., omeprazole 20 mg to 40 mg PO once daily before breakfast, or esomeprazole 40 mg PO once daily. For refractory symptoms or extensive C and M lengths, twice-daily dosing (e.g., omeprazole 40 mg PO twice daily) is recommended.
    • Adjunctive nocturnal histamine H2-receptor antagonist therapy (e.g., famotidine 20 mg to 40 mg PO at bedtime) may be utilized for refractory nocturnal acid breakthrough, though PPIs remain foundational.
    • Lifestyle modifications including weight loss, elevation of the head of the bed by 15 to 20 centimeters, cessation of smoking, avoidance of late-night meals, and restriction of dietary triggers (caffeine, alcohol, chocolate, fatty foods).
  • Surgical / Interventional Indications:
    • Endoscopic Eradication Therapy (EET): Indicated for confirmed high-grade dysplasia or low-grade dysplasia confirmed on repeat specialist pathology. Combined endoscopic mucosal resection (EMR) for visible mucosal nodules followed by radiofrequency ablation (RFA) to eradicate remaining flat metaplastic and dysplastic mucosa.
    • Anti-reflux surgery (Laparoscopic Nissen fundoplication): Considered in select patients with severe, medically refractory GORD symptoms, large mechanical hiatus hernias, or medication intolerance, though it does not eliminate the requirement for ongoing endoscopic surveillance if Barrett oesophagus is established.
    • Oesophagectomy: Reserved for patients with confirmed invasive oesophageal adenocarcinoma or high-grade dysplasia refractory to multiple endoscopic eradication modalities.

Complications & Prognosis

  • Malignant Transformation: Progression from non-dysplastic Barrett oesophagus to low-grade dysplasia, high-grade dysplasia, and invasive oesophageal adenocarcinoma represents the most feared and clinically significant long-term complication, occurring at an estimated annual incidence of 0.5% to 1.0% in patients with specialised intestinal metaplasia.
  • Peptic Stricture Formation: Chronic transmural inflammation and fibrosis at the squamocolumnar junction lead to luminal narrowing, causing progressive solid-food dysphagia requiring therapeutic endoscopic balloon dilatation.
  • Barrett Ulceration: Deep mucosal ulceration within the columnar-lined segment can lead to chronic iron-deficiency anaemia, acute upper gastrointestinal haemorrhage, or rarely transmural perforation.
  • Prognosis: The overall prognosis for non-dysplastic Barrett oesophagus managed with appropriate acid suppression and adherence to surveillance intervals is excellent, with normal life expectancies. Conversely, patients who develop invasive oesophageal adenocarcinoma face a significantly guarded prognosis, underscoring the critical importance of rigorous Prague classification documentation, guideline-directed surveillance, and timely endoscopic eradication therapy.